Daewoong Pharma

Daewoong Pharma maintains a capital structure characterized by significant leverage, with long-term debt of 829.4 billion KRW against total equity of 1.01 trillion KRW, resulting in a debt-to-equity ratio of 0.82. The company holds 168.9 billion KRW in cash and equivalents, which is insufficient to cover total liabilities of 1.36 trillion KRW, leading to a negative net cash position. Liquidity is assessed as medium, supported by a current ratio of 1.24, indicating adequate short-term asset coverage for current liabilities. The firm generates 149.2 billion KRW in operating cash flow, but heavy capital expenditures of 191.5 billion KRW reduce free cash flow to 43.6 billion KRW.

Profitability metrics demonstrate strong returns on capital, with a return on equity of 19.47% and a return on assets of 8.29%. The company reports a net income of 195.9 billion KRW on revenue of 1.57 trillion KRW, yielding a net margin of approximately 12.5%. Operating income stands at 232.4 billion KRW, reflecting an operating margin of roughly 14.8%. The gross profit of 822.5 billion KRW indicates a gross margin of 52.4%, suggesting efficient cost of goods sold management relative to revenue.